Literature DB >> 22577237

Integration of 3-dimensional scar models from SPECT to guide ventricular tachycardia ablation.

Jing Tian1, Mark F Smith, Ghada Ahmad, Vasken Dilsizian, Alejandro Jimenez, Timm Dickfeld.   

Abstract

UNLABELLED: The integration of myocardial scar models in 3-dimensional (3D) mapping systems may provide a novel way of helping to guide ventricular tachycardia (VT) ablations. This study assessed the value of (201)Tl SPECT perfusion imaging to define ventricular myocardial scar areas and to characterize electrophysiology voltage-derived myocardial substrate categories of scar, border zone (BZ), and normal myocardium regions. Scar and BZ regions have been implicated in the genesis of ventricular arrhythmias.
METHODS: Ten patients scheduled for VT ablation underwent (201)Tl SPECT before the ablation procedure. 3D left ventricular (LV) scar models were created from the SPECT images. These scar models were registered with the LV voltage maps and analyzed with a 17-segment cardiac model. Scar location and scar burden were compared between the SPECT scar models and voltage maps. In addition, (201)Tl SPECT uptake was quantified using a 68-segment cardiac model and compared among voltage-defined scar, BZ, and normal segments.
RESULTS: 3D models of LV myocardium and scar were successfully created from (201)Tl SPECT images and integrated in a clinical mapping system. The surface registration error with the electrophysiology voltage map was 4.4 ± 1.0 mm. The 3D scar location from SPECT matched in 72% of the segments with the voltage map findings. All successful ablation sites were located within the SPECT-defined scar or within 1 cm of its border, with 73% of the successful ablation sites within 1 cm of the scar border. Voltage measurements in SPECT-defined scar and normal areas were 1.2 ± 1.7 and 3.4 ± 2.8 mV, respectively (P < 0.001). The fractional SPECT scar burden area (18.8% ± 5.2%) agreed better with the abnormal (scar plus BZ) voltage area (20.8% ± 15.7%) than with the scar voltage area (5.8% ± 5.8%). Mean normalized (201)Tl uptake was 55% ± 21% in the voltage-defined scar, 63% ± 20% in BZ, and 79% ± 17% in normal myocardial segments (P < 0.05 for scar or BZ vs. normal).
CONCLUSION: 3D SPECT surface models of LV scar were accurately integrated into a clinical mapping system and predicted endocardial voltage-defined scar. These preliminary data support the possible use of widely available (201)Tl SPECT to facilitate substrate-guided VT ablations.

Entities:  

Mesh:

Year:  2012        PMID: 22577237     DOI: 10.2967/jnumed.111.094904

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

1.  Ventricular arrhythmia originating from scar border tissue during dobutamine myocardial perfusion gated SPECT on CZT camera.

Authors:  Damien Legallois; Laure Champ-Rigot; Benjamin Houdu; Denis Agostini; Alain Manrique
Journal:  J Nucl Cardiol       Date:  2015-12-03       Impact factor: 5.952

2.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

3.  I-123 mIBG and Tc-99m myocardial SPECT imaging to predict inducibility of ventricular arrhythmia on electrophysiology testing: a retrospective analysis.

Authors:  Yanli Zhou; Weihua Zhou; Russell D Folks; Daya N Manatunga; Arnold F Jacobson; Jeroen J Bax; Ernest V Garcia; Ji Chen
Journal:  J Nucl Cardiol       Date:  2014-05-24       Impact factor: 5.952

Review 4.  [Three-dimensional mapping systems].

Authors:  Philipp Halbfass; Oliver Turschner; Christian Mahnkopf; Johannes Brachmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-11-28

Review 5.  Nuclear Imaging Guidance for Ablation of Ventricular Arrhythmias.

Authors:  John Duell; Vasken Dilsizian; Mark Smith; Wengen Chen; Timm Dickfeld
Journal:  Curr Cardiol Rep       Date:  2016-02       Impact factor: 2.931

6.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Sáenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

7.  Imaging-guided Ventricular Tachycardia Ablation.

Authors:  Sebastiaan Rd Piers; Katja Zeppenfeld
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-11-29

Review 8.  The potential role of iodine-123 metaiodobenzylguanidine imaging for identifying sustained ventricular tachycardia in patients with cardiomyopathy.

Authors:  Thomas Klein; Vasken Dilsizian; Qi Cao; Wengen Chen; Timm-Michael Dickfeld
Journal:  Curr Cardiol Rep       Date:  2013-05       Impact factor: 2.931

Review 9.  Principles and techniques of imaging in identifying the substrate of ventricular arrhythmia.

Authors:  Mischa T Rijnierse; Cornelis P Allaart; Paul Knaapen
Journal:  J Nucl Cardiol       Date:  2015-12-14       Impact factor: 5.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.